Phase I trial of continuous infusion carboplatin and etoposide in children with refractory acute leukemia: A Pediatric Oncology Group study

Nursing and Health Professions

• Patient 100%
• Carboplatin 41%
• Dose 33%
• Child 33%
• Toxicity 16%
• Continuous Infusion 16%
• Intravenous Drug Administration 16%
• Remission 16%
• Acute Leukemia 16%
• Etoposide 16%
• Infection 8%
• Bleeding 8%
• Diarrhea 8%
• Childhood Cancer 8%
• Procedures 8%
• Aplasia 8%
• Antileukemic Agent 8%

Medicine and Dentistry

• Carboplatin 41%
• Spontaneous Remission 16%
• Continuous Infusion 16%
• Toxicity 16%
• Intravenous Drug Administration 16%
• Acute Leukemia 16%
• Phase I Trials 16%
• Etoposide 16%
• Therapeutic Procedure 16%
• Bleeding 8%
• Childhood Cancer 8%
• Infection 8%
• Diarrhea 8%
• Life 8%
• Aplasia 8%
• Antileukemic Agent 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Carboplatin 41%
• Phase II Trials 16%
• Toxicity 16%
• Acute Leukemia 16%
• Remission 16%
• Etoposide 16%
• Diarrhea 8%
• Infection 8%
• Bleeding 8%
• Childhood Cancer 8%
• Aplasia 8%